Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Sees Large Decline in Short Interest

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) was the target of a significant drop in short interest in January. As of January 31st, there was short interest totalling 513,900 shares, a drop of 12.5% from the January 15th total of 587,000 shares. Currently, 6.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 278,700 shares, the days-to-cover ratio is currently 1.8 days.

Institutional Investors Weigh In On Citius Pharmaceuticals

Several hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC lifted its stake in Citius Pharmaceuticals by 14.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,878,953 shares of the company’s stock worth $941,000 after acquiring an additional 232,656 shares in the last quarter. Chelsea Counsel Co. lifted its stake in Citius Pharmaceuticals by 9.8% in the 3rd quarter. Chelsea Counsel Co. now owns 281,300 shares of the company’s stock worth $141,000 after acquiring an additional 25,000 shares in the last quarter. Wealth Advisory Solutions LLC lifted its stake in Citius Pharmaceuticals by 33.1% in the 3rd quarter. Wealth Advisory Solutions LLC now owns 201,000 shares of the company’s stock worth $101,000 after acquiring an additional 50,000 shares in the last quarter. Arkadios Wealth Advisors lifted its stake in Citius Pharmaceuticals by 33.3% in the 3rd quarter. Arkadios Wealth Advisors now owns 200,000 shares of the company’s stock worth $100,000 after acquiring an additional 50,000 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in Citius Pharmaceuticals in the 3rd quarter worth about $50,000. 16.88% of the stock is owned by hedge funds and other institutional investors.

Citius Pharmaceuticals Stock Down 8.0 %

Shares of NASDAQ CTXR traded down $0.22 during mid-day trading on Tuesday, hitting $2.48. 152,421 shares of the company traded hands, compared to its average volume of 102,549. Citius Pharmaceuticals has a 1 year low of $2.42 and a 1 year high of $26.75. The stock has a market capitalization of $21.26 million, a price-to-earnings ratio of -0.41 and a beta of 1.28. The business has a 50 day moving average of $3.14 and a two-hundred day moving average of $8.36.

Citius Pharmaceuticals (NASDAQ:CTXR) last announced its earnings results on Friday, February 14th. The company reported ($1.30) EPS for the quarter, missing the consensus estimate of ($1.25) by ($0.05). As a group, research analysts anticipate that Citius Pharmaceuticals will post -4.5 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on CTXR shares. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 target price on shares of Citius Pharmaceuticals in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of Citius Pharmaceuticals in a research note on Tuesday, November 12th.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.